Aurora kinase modulators and method of use

US7981891B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Holly L. Deak · Brookline, US
• Stephanie Geuns-Meyer · Medford, US
• Brian L. Hodous · Cambridge, US
• Zihao Hua · Andover, US
• Mathew Martin · Cambridge, US
• Hanh Nho Nguyen · North Palm Beach, US
• Philip R. Olivieri · Boston, US
• Kate Panter · Cambridge, US
• Karina Romero · Cambridge, US
• Laurie B. Schenkel · Somerville, US
• Ryan White · Thousand Oaks, US

Key dates

• Filing date: Jun 30, 2010
• Grant date: Jul 19, 2011
• Expiry date: Jun 30, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to chemical compounds having a general formula Iwherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.